SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations, but weaker forward guidanceparticularly the Q4 outlookprompted a sharp post-report selloff. Traders are split between viewing the drop as justified by slowing growth and buying it as an overreaction to an otherwise solid quarter.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results drew attention after traders highlighted a sizable earnings and revenue beat, though the share reaction was muted and volatile. The debate centers on whether strong growth can outweigh heavy spending, valuation concerns and a looming share unlock.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound has focused attention on the approaching 80-event trigger for SELLASs Phase 3 REGAL trial and its eventual final analysis, with traders also pointing to SLS009 updates as potential catalysts. Buyout and data-leak theories are circulating, but no deal or new trial result is confirmed; some traders view the move as a speculative rebound without company news.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets continued share-price weakness and struggle around technical support are driving discussion, with traders divided between dip-buying on valuation and AI/cloud prospects and bearish views focused on poor relative performance and heavy AI spending. Many are looking to the upcoming earnings report for clarity on growth and investment returns, while broader tech-market weakness is also in focus.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are selling off despite plans to pursue a Monee financial-services IPO and launch an AI cloud business. Traders debate whether the moves could unlock value or instead add uncertainty and spending, while many point to the stocks sharp technical breakdown; some view the decline as an overreaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being attributed mainly to strength across biotech, with traders also citing Silence Therapeutics acquisition as a signal of broader pharma interest in siRNA. The community is divided on whether the move reflects sector momentum or company-specific buying; speculation about a data leak remains unconfirmed.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs sharp selloff and underperformance versus other AI data-center peers are fueling debate amid concerns about neocloud funding, AI infrastructure returns and potential sector consolidation. Traders are split over whether the decline reflects business, dilution and execution risks or an oversold move; bulls cite co-CEO Daniel Roberts comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while skeptics remain unconvinced.

Alphabet Inc - Ordinary Shares - Class C

Alphabets pullback ahead of earnings has traders debating whether Google Cloud and Gemini growth can justify heavy AI infrastructure spending. Bulls view the weakness as a buying opportunity, while bears worry that rising capex, uncertain AI returns and broader AI financing concerns could weigh on the stock.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

The FAAs certification of Boeings 737 MAX 10 is driving attention, with traders debating its significance because the model represents a substantial part of the MAX backlog. The stocks weak reaction has fueled a sell the news discussion, as many focus on whether Boeing can increase production and deliveries enough to improve cash generation.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a Q3 earnings beat as traders focus on the narrowed full-year profit outlook, whose midpoint was unchanged, rather than the new buyback authorization. Some traders view the drop as an overreaction and cite the buyback and stronger cash-flow outlook, while others say the cautious outlook outweighs those positives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Equity

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies.</li><li>The pharma giant said the acquisition strengthens its neuroscience pipeline with two late-stage programs targeting treatment-resistant depression.</li><li>Over the past year, Compass has significantly outperformed ATAI.</li></ul>Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in cash at closing, plus up to $2.50 per share tied to future development and regulatory milestones for ATAI's two lead programs, bringing total potential value to as much as $9.25 per share.&nbsp;Based on ATAI's Wednesday close of around $5.36, the $6.75 per share cash offer represents a premium of approximately 25.9%. Taking total potential consideration of $9.25 into account, the premium to Wednesday's close would be approximately 72.6%.The deal is expected to close in the third quarter (Q3), pending shareholder and regulatory approval.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/ATAI_2026_07_16_06_37_17_png_4cad859a33.webp" alt="ATAI_2026-07-16_06-37-17.png" width="2643" height="1588"><figcaption>ATAI stock historical performance vs. pre-market on July 16. | Source: TradingView</figcaption></figure><a href="https://stocktwits.com/symbol/ATAI/">ATAI stock</a> jumped over 33% in pre-market trade, paring gains from a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-atai-stock-soaring-59-after-hours/cZZPl7dR7rk">jump of around 60%</a> earlier in the day. If pre-market grains hold, ATAI’s stock is on track to hit its highest levels since December 2021 and mark the biggest single-day jump in the company’s history.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_063534529_png_3a8bd239cd.webp" alt="koyfin_20260716_063534529.png" width="2400" height="1240"><figcaption>ATAI stock historical single-day stock price changes. | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/LLY">LLY's stock</a> was also among the top trending tickers on Stocktwits, edging higher by around 0.4% in pre-market trade.<h2 class="st-heading-2">What is Lilly Buying?</h2>ATAI's lead asset is BPL-003, an intranasal, synthetic form of 5-MeO-DMT for treatment-resistant depression that has already earned FDA Breakthrough Therapy Designation and entered Phase 3 activities, following a Phase 2b study showing rapid and durable symptom reduction after a roughly two-hour in-clinic session.&nbsp;Its second program, VLS-01, is a buccal film formulation of DMT currently in Phase 2b. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, Lilly Neuroscience's president.&nbsp;ATAI co-founder and CEO Srinivas Rao said the deal gives the company's pipeline "the resources and scale" to move faster than it could independently.<h2 class="st-heading-2">Why Is CMPS Stock Rallying Too?</h2><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> gained more than 7% in pre-market trade, and the move isn't purely coincidental. ATAI has historically been Compass's largest shareholder, though its stake has fallen from a peak of roughly 29% to 4.96% as of a February 2026 filing, dropping it below the 5% threshold requiring continued disclosure of its position.CMPS shares are also riding a separate, broader tailwind. Regulatory momentum for psychedelic therapies has been building steadily since President Donald Trump signed an executive order in April directing the Federal Drug Administration (FDA) to fast-track review of psychedelic drugs with Breakthrough Therapy designation.&nbsp;Earlier this week, the FDA announced a public hearing on psychedelic therapies and published final clinical guidance for developers on July 14. The Department of Health and Human Services (HHS) and the Department of Veterans Affairs also announced a new collaboration in anticipation of the first investigational drug approvals.&nbsp;<h2 class="st-heading-2">How Does Retail Feel About AtaiBeckley-Eli Lilly Deal?</h2>Retail sentiment around ATAI stock on Stocktwits rose to ‘extremely bullish’ from ‘bullish’ territory over the past day. Chatter stayed at ‘extremely high’ levels. Meanwhile, sentiment around CMPS stock fell to ‘neutral’ from ‘bullish’ territory, accompanied by chatter at ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_07_16_072103_png_95d0276b5f.webp" alt="Screenshot 2026-07-16 072103.png" width="1272" height="690"><figcaption>ATAI stock retail sentiment on July 16 as of 7:30 a.m. ET | Source: Stocktwits&nbsp;</figcaption></figure>Retail traders on the platform expressed excitement about what the takeover could mean for AtaiBeckley’s future growth.<stembedurl>https://www.stocktwits.com/LoadedUP1000/message/659184838</stembedurl><h2 class="st-heading-2">Comparing The Fundamentals</h2>The two companies sit at different stages of development. ATAI’s stock carries a ‘Strong Buy’ rating from two analysts, and a ‘Buy’ rating from 12 out of the 14 analysts covering the stock, according to Koyfin data. The average price target for the shares is around $14.17, and a trailing one-year return of about 102%.Wall Street was similarly bullish on Compass as well. CMPS Stock carries a ‘Strong Buy’ rating from three analysts and a ‘Buy’ rating from 12 out of the 15 analysts covering the stock. The average price target for the shares is around $24.47, implying a roughly 84% potential upside from Wednesday's close.Neither company currently generates meaningful revenue. Compass has posted essentially $0 in quarterly sales across every quarter tracked since early 2025, reflecting its status as a clinical-stage company with no approved products yet. Consensus estimates project continued losses, including a projected adjusted loss of $0.31 per share for the quarter ending June 30.&nbsp;ATAI shows a similar profile, with quarterly sales in the range of just $0 to $2 million and a projected adjusted loss of $0.11 per share for the same period.Over the past year, Compass has significantly outpaced ATAI since mid-April, gaining nearly 93% year-to-date versus ATAI's roughly 31%<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_061620094_png_c1a394bb97.webp" alt="koyfin_20260716_061620094.png" width="2400" height="1240"><figcaption>CMPS stock vs. ATAI stock performance year-to-date. | Source: Koyfin</figcaption></figure>Unlike ATAI, which will now become part of Eli Lilly, Compass remains an independent, publicly traded company focused on developing psychedelic therapies for treatment-resistant mental health conditions.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-says-53-b-offer-for-pay-pal-is-simply-too-low/cZZPR3LR7Ai">Michael Burry Says $53B Offer For PayPal Is 'Simply Too Low' – ‘The Big Short’ Investor Expects Higher Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)

Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.

AtaiBeckley Inc.

COMPASS Pathways

Lilly(Eli) & Co

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

AdvisorShares Psychedelics ETF

SPDR Pharmaceuticals ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.99
Prev Close	$13.69
Open	$13.80
Dividend Yield	N/A
50-Day Moving Average	$18.42
Beta	N/A
Avg. Volume	49,339.10
PE Ratio	N/A

52-Week High	$24.15
52-Week Low	$7.75
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

PILL Fundamentals